Blog

The debate over cannabis scheduling in the United States has entered a new, unpredictable chapter under President Trump. At an August press conference, he promised a “determination” on cannabis scheduling within weeks, while emphasizing he had “heard great things” about medical cannabis and “bad things” about nearly everything else. That contradiction captures the essence of the current moment: cannabis is a political hot potato, a medical lifeline, and a regulatory puzzle. Patients, providers, businesses, and policymakers are waiting to see whether the next move will finally align federal law with science and lived reality—or lead to decades of more dysfunction.

This article breaks down ten essential things you need to know to understand what’s at stake and what could happen next. From the actual powers the President and the DEA Administrator hold, to the influences shaping the process, to the reasons cannabis was ever in Schedule I, we’ll unpack the moving parts. You’ll also see why a shift to Schedule III or II is not the neat solution some imagine, why keeping cannabis in Schedule I would be disastrous, and why none of the current schedules fit. Ultimately, the story ends where it began: with Congress. Because no matter what the White House or DEA decides, only Congress can establish a durable national framework for medical cannabis that truly protects patients and integrates this medicine into U.S. healthcare.  Continue Reading...